{"id":"NCT04512001","sponsor":"Fresenius Kabi SwissBioSim GmbH","briefTitle":"MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis","officialTitle":"A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union-approved RoActemra® in Patients With Moderately to Severely Active Rheumatoid Arthritis (APTURA I Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-03","primaryCompletion":"2021-08-31","completion":"2022-06-06","firstPosted":"2020-08-13","resultsPosted":"2022-10-24","lastUpdate":"2023-06-27"},"enrollment":604,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"MSB11456","otherNames":[]},{"type":"DRUG","name":"EU-approved RoActemra","otherNames":[]}],"arms":[{"label":"MSB11456","type":"EXPERIMENTAL"},{"label":"RoActemra®","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis.\n\nParticipants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.","primaryOutcome":{"measure":"Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)","timeFrame":"Baseline; Week 24","effectByArm":[{"arm":"Core Treatment Period: MSB11456","deltaMin":-3.53,"sd":0.106},{"arm":"Core Treatment Period: RoActemra®","deltaMin":-3.54,"sd":0.106}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":85,"countries":["Bulgaria","Czechia","Georgia","Hungary","Moldova","Poland","Russia","Serbia","Slovakia"]},"refs":{"pmids":["38316489"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":302},"commonTop":["Alanine aminotransferase increased","COVID-19","Leukopenia","Aspartate aminotransferase increased","Neutropenia"]}}